✦ LIBER ✦

Geographical variation in adverse event reporting rates in clinical trials

✍ Scribed by Svante Joelson; Ing-Britt Joelson; Mari-Ann Wallander

Book ID: 101289510
Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 154 KB
Volume: 6
Category: Article
ISSN: 1053-8569
DOI: 10.1002/(sici)1099-1557(199710)6:3+<s31::aid-pds288>3.0.co;2-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

How Should Adverse Events Be Reported in

How Should Adverse Events Be Reported in US Clinical Trials?: Ethical Considerations

✍ Shamoo, AE; Katzel, LI 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 104 KB

Adverse event monitoring in clinical tri

Adverse event monitoring in clinical trials of felodipine and omeprazole

✍ M.-A. Wallander; P. Lundborg; K. Svärdsudd 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 660 KB

Although most clinical trials encompass aspects of safety, methods for assessing the safety of a drug by recording adverse events have been poorly studied. It has been suggested that adverse events rather than adverse drug reactions should be monitored, since a reliable determination of which events

Low incidence of adverse events after ve

Low incidence of adverse events after venography in orthopedic clinical trials

✍ M. J. MANT; D. B. RUSSELL; P. DONAHUE; E. WIEBE 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Quality of Methods for Assessing and Rep

Quality of Methods for Assessing and Reporting Serious Adverse Events in Clinical Trials of Cancer Drugs

✍ Belknap, S M; Georgopoulos, C H; West, D P; Yarnold, P R; Kelly, W N 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 133 KB

Reporting time-to-event endpoints and re

Reporting time-to-event endpoints and response rates in 4 decades of randomized controlled trials in advanced colorectal cancer

✍ Hendrik-Tobias Arkenau; Ina Nordman; Timothy Dobbins; Robyn Ward 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 244 KB

## Abstract ## BACKGROUND: Reporting of randomized controlled clinical trials (RCTs) often is suboptimal. Cancer drug trials are complicated further by multiple survival and response endpoints. The authors of this report determined the frequency of reporting of time‐to‐event endpoints and tumor re

Cognitive testing in early phase clinica

Cognitive testing in early phase clinical trials: outcome according to adverse event profile in a Phase I study

✍ Alex Collie; Paul Maruff; Peter J. Snyder; Miss Amanda Darekar; John P. Huggins 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

## Abstract ## Background It has been proposed that objective cognitive testing provides additional information to that collected via adverse event (AE) recordings. However, in clinical trials of compounds with potentially negative effects on cognition, the results of cognitive testing may overlap